Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.45 |
| ▸ | FAP | Q12884 | 8/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.45 |
| ▸ | PREP | P48147 | 4/20 | 0.45 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186760 | 1.00 | DPP4 (0.45) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL5144665 | 1.00 | DPP4 (0.45) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL20186757 | 1.00 | DPP4 (0.45) | DPP4DPP7FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL14121567 | 0.98 | DPP4 (0.44) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26187057 | 0.88 | DPP4 (0.40) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26187052 | 0.88 | DPP4 (0.40) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26187045 | 0.88 | DPP4 (0.40) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL2830584 | 0.84 | RAB9A (0.44) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL3601155 | 0.84 | RAB9A (0.44) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL29481543 | 0.84 | ACE (0.41) | DPP4DPP7FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | DPP4 3119/4885DPP7 2768/4885FAP 1130/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | DPP4 3119/4885DPP7 2768/4885FAP 1130/4885 |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DPP4 497/4885DPP7 584/4885FAP 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.